EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study

Sukran Senyurek, Sezer Saglam, Esra Kaytan Saglam, Hakan Yanar, Kaan Gok, Didem Tastekin, Canan Koksal Akbas, Nergiz Dagoglu Sakin, Gulbiz Dagoglu Kartal, Emre Balik, Metin Keskin, Yasemin Sanli und 2 weitere

Oncology Research · 2023

DOI: 10.32604/or.2023.030351 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Oncology Research, 2023. Verfasst von Sukran Senyurek und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Koc University School of Medicine, Istanbul, 34450, Türkiye. Hauptthemen laut MEDLINE: Quality of Life, Rectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeRectal NeoplasmsHumansCapecitabineAnal CanalNeoadjuvant TherapyOrgan Sparing TreatmentsFluorouracilChemoradiotherapyNeoplasm StagingTreatment OutcomeAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

ChemoradiotherapyNeoadjuvant therapyRectal cancer

Substanzen

CapecitabineFluorouracil

Autor:innen und Institutionen

  • Department of Radiation Oncology, Koc University School of Medicine, Istanbul, 34450, Türkiye.
  • Department of Medical Oncology, Demiroglu Bilim University Faculty of Medicine, Istanbul, 34394, Türkiye.
  • Department of Radiation Oncology, Istanbul University Oncology Institute, Istanbul, 34093, Türkiye.
  • Department of General Surgery, Istanbul University Istanbul Faculty of Medicine, Istanbul, 34093, Türkiye.
  • Department of Medical Oncology, Istanbul University Oncology Institute, Istanbul, 34093, Türkiye.
  • Department of Medical Physics, Istanbul University Oncology Institute, Istanbul, 34093, Türkiye.

Zitieren

APA

Senyurek, S., Saglam, S., Saglam, E. K., Yanar, H., Gok, K., Tastekin, D., Akbas, C. K., Sakin, N. D., Kartal, G. D., Balik, E., Keskin, M., Sanli, Y., Gulluoglu, M., & Akgun, Z. (2023). Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study. Oncology Research. https://doi.org/10.32604/or.2023.030351

Vancouver

Senyurek S, Saglam S, Saglam EK, Yanar H, Gok K, Tastekin D, et al. Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study. Oncology Research. 2023. doi:10.32604/or.2023.030351

BibTeX
@article{Senyurek2023,
  author = {Senyurek, Sukran and Saglam, Sezer and Saglam, Esra Kaytan and Yanar, Hakan and Gok, Kaan and Tastekin, Didem and Akbas, Canan Koksal and Sakin, Nergiz Dagoglu and Kartal, Gulbiz Dagoglu and Balik, Emre and Keskin, Metin and Sanli, Yasemin and Gulluoglu, Mine and Akgun, Zuleyha},
  title = {Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study},
  journal = {Oncology Research},
  year = {2023},
  doi = {10.32604/or.2023.030351}
}
Kostenlos starten →